# **Complete Summary**

#### **GUIDELINE TITLE**

Use of photoscreening for children's vision screening.

# BIBLIOGRAPHIC SOURCE(S)

Use of photoscreening for children's vision screening. Pediatrics 2002 Mar; 109(3):524-5. [15 references]

# **COMPLETE SUMMARY CONTENT**

SCOPE

METHODOLOGY - including Rating Scheme and Cost Analysis RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
QUALIFYING STATEMENTS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY

# **SCOPE**

# DISEASE/CONDITION(S)

Amblyopia, strabismus, media opacities, significant refractive errors, and other treatable ocular disease processes

#### **GUIDELINE CATEGORY**

Evaluation Screening

# CLINICAL SPECIALTY

Ophthalmology Pediatrics

# INTENDED USERS

Advanced Practice Nurses Nurses Physician Assistants Physicians

#### GUI DELI NE OBJECTI VE(S)

To present recommendations for the use of photoscreening as a technique for the detection of amblyopia and strabismus in children

#### TARGET POPULATION

Infants and children, especially preschool-aged children and children with developmental delays

#### INTERVENTIONS AND PRACTICES CONSIDERED

Photoscreening

#### MAJOR OUTCOMES CONSIDERED

- Vision screening rates
- Amblyogenic risk factors
- False-positive and false-negative result rates of photoscreening (sensitivity, specificity, and predictive values of tests)

# METHODOLOGY

#### METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

Not stated

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Not stated

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not applicable

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not stated

#### RECOMMENDATIONS

#### MAJOR RECOMMENDATIONS

- 1. Vision screening should be performed at the earliest possible age and at regular intervals during childhood as recommended by the American Academy of Pediatrics (AAP). The goal remains to eliminate preventable blindness and treatable visual disability.
- 2. Photoscreening is an innovative tool that can facilitate vision screening in children, especially in children who are difficult to screen (i.e., infants, toddlers, and children with developmental delays). Photoscreening systems are one option to increase the screening rate in preschool-aged children.
- 3. Regardless of the type of photoscreening system used, the evaluator must know how to properly apply the technology and understand the limitations of the test, such as the possible occurrence of false-positive and false-negative results as they apply to the population being tested.
- 4. Photoscreening needs to be studied more extensively. The American Academy of Pediatrics favors additional research of photoscreening devices and other vision screening methods in large, controlled studies to elucidate validity of results, efficacy, and cost-effectiveness for identifying amblyogenic factors in different age groups as well as subgroups of children. The goal remains to eliminate preventable childhood blindness and treatable visual disability.

CLINICAL ALGORITHM(S)

None provided

# EVIDENCE SUPPORTING THE RECOMMENDATIONS

# TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

Not stated

# BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

#### POTENTIAL BENEFITS

- Detection of poor vision or risk factors that interfere with vision and normal visual development
- Increase in vision screening rates in infants, preverbal children, and those with developmental delays who are most difficult to screen

Subgroups Most Likely to Benefit:

Children at high risk for eye problems, such as premature infants or children with developmental delays or a family history of eye problems

#### POTENTIAL HARMS

Potential for false-positive or false-negative test results

# QUALIFYING STATEMENTS

# QUALIFYING STATEMENTS

The recommendations in this statement do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

# IMPLEMENTATION OF THE GUIDELINE

# DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

# INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

**IOM CARE NEED** 

Staying Healthy

IOM DOMAIN

Effectiveness

#### IDENTIFYING INFORMATION AND AVAILABILITY

# BIBLIOGRAPHIC SOURCE(S)

Use of photoscreening for children's vision screening. Pediatrics 2002 Mar; 109(3):524-5. [15 references]

#### **ADAPTATION**

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2002 Mar

GUI DELI NE DEVELOPER(S)

American Academy of Pediatrics - Medical Specialty Society

SOURCE(S) OF FUNDING

American Academy of Pediatrics

**GUI DELI NE COMMITTEE** 

Committee on Practice and Ambulatory Medicine

Section on Ophthalmology

#### COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Committee on Practice and Ambulatory Medicine Members, 2001-2002: Jack T. Swanson, MD, Chairperson; F. Lane France, MD; Katherine C. Teets Grimm, MD; Norman Harbaugh, MD; Thomas Herr, MD; John Jakubec, MD; Allan S. Lieberthal, MD; Kyle Yasuda, MD

Liaisons: Adrienne A. Bien; Todd Davis, MD; Winston Price, MD.

Staff: Bob Sebring

Section on Ophthalmology, 2001-2002: Gary T. Denslow, MD, MPH, Chairperson; Steven J. Lichtenstein, MD, Chairperson-elect; Jay Bernstein, MD; Edward G. Buckley, MD; George S. Ellis, Jr, MD; Gregg T. Lueder, MD; James B. Ruben, MD

Liaisons: Jane D. Kivlin, MD; Michael Redmond, MD

Consultants: Allan M. Eisenbaum, MD; Walter M. Fierson, MD; Harold P. Koller, MD, Immediate Past Chairperson

Staff: Stephanie Mucha, MPH

# FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

#### **GUIDELINE STATUS**

This is the current release of the guideline.

American Academy of Pediatrics (AAP) Policies are reviewed every 3 years by the authoring body, at which time a recommendation is made that the policy be retired, revised, or reaffirmed without change. Until the Board of Directors approves a revision or reaffirmation, or retires a statement, the current policy remains in effect.

#### **GUIDELINE AVAILABILITY**

Electronic copies: Available from the <u>American Academy of Pediatrics (AAP) Policy Web site</u>.

Print copies: Available from AAP, 141 Northwest Point Blvd., P.O. Box 927, Elk Grove Village, IL 60009-0927.

#### AVAILABILITY OF COMPANION DOCUMENTS

None available

#### PATIENT RESOURCES

None available

# NGC STATUS

This summary was completed by ECRI on July 22, 2002.

# COPYRIGHT STATEMENT

This National Guideline Clearinghouse (NGC) summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please contact the Permissions Editor, American Academy of Pediatrics (AAP), 141 Northwest Point Blvd, Elk Grove Village, IL 60007.

© 1998-2004 National Guideline Clearinghouse

Date Modified: 11/8/2004

# FIRSTGOV

